<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01274923</url>
  </required_header>
  <id_info>
    <org_study_id>0200-09-rmb europe</org_study_id>
    <nct_id>NCT01274923</nct_id>
  </id_info>
  <brief_title>Double Blind Placebo Controlled Study on the Effect of Extracorporal Shock Wave Therapy on Erectile Dysfunction in PDE5i Responders</brief_title>
  <acronym>LI-ESWT</acronym>
  <official_title>The Effect of Low Intensity Shock Wave Therapy on Erectile Dysfunction in Patients Responding to PDE5i's</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medispec</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the effect of shockwave therapy on erectile dysfunction on
      patients responding to PDE5i therapy in a sham controlled randomized double blind manner.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to evaluate the effect of a 12-session low intensity shockwave therapy
      protocol for patients with erectile dysfunction. On screening patients will undergo
      evaluation by thorough medical history and by questionnaires for evaluation of sexual
      function. A one-month active treatment with PDE5i will be provided followed by re-evaluation
      using the same questionnaires. Then another one-month period without PDE5i medication
      (washout period ) will be done and finally on the following visit evaluation will include the
      same questionnaires and if fit for inclusion- additional objective evaluation of endothelial
      function using the Flow mediated dilatation technique and penile blood flow measurement by
      doppler ultrasound of the Penis will be performed. At the end of this screening pahse the
      first shock wave session will be performed. Altogether 12 treatment sessions will be
      performed - 6 treatments twice a week followed by a 3 week no-treatment interval and again 6
      treatments twice a week. Follow-up which will include the same evaluation as in the first
      treatment visit will be performed one month after end of treatment
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International Index of Erectile function- Erectile Function Domain</measure>
    <time_frame>At screening and 17 weeks later at last visit</time_frame>
    <description>An increase in score of 5points and above will be considered success.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rigidity scale</measure>
    <time_frame>At screening and 17 weeks later at last visit</time_frame>
    <description>A change from 1,2 to a result of 3 or 4 of the rigidity scale points will be considered success</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow Mediated Dilatation Technique</measure>
    <time_frame>At screening and 17 weeks later at last visit</time_frame>
    <description>A specialized sphygmomanometer cuff located at the penile base, is inflated to 50 mm Hg for 5min to induce a venous filling. A mercury strain gauge is placed at least 1-2 cm above the penile cuff. Baseline penile blood flow is obtained. Postischemic penile blood flow is then recorded immediately after the deflation, until a return to baseline flow is observed. An increase in blood flow above 30% will be considered success.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>shock wave treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;MEDISPEC&quot; Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>&quot;MEDISPEC&quot; Probe does not deliver energy but creates same noise and sensation of active probe</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>&quot;MEDISPEC&quot; treatment probe</intervention_name>
    <description>shock wave treatment</description>
    <arm_group_label>shock wave treatment</arm_group_label>
    <arm_group_label>&quot;MEDISPEC&quot; Sham</arm_group_label>
    <other_name>Omnispec model ED1000</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ED of more than 6 months

          -  Rigidity score ≥ 3 under PDE5i therapy

          -  SHIM ≤21 under PDE5i therapy

          -  Non- hormonal, neurological or psychological pathology

          -  Stable heterosexual relationship for more than 3 months

        Exclusion Criteria:

          -  Prior prostatectomy surgery

          -  Any unstable medical, psychiatric, spinal cord injury and penile anatomical
             abnormalities

          -  Clinically significant chronic hematological disease

          -  Anti-androgens, oral or injectable androgens

          -  Radiotherapy in pelvic region
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ilan Gruenwald, MD</last_name>
    <phone>00972544474341</phone>
    <email>i_gruenwald@rambam.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yoram Gruenwald, Prof</last_name>
    <phone>0097248542819</phone>
    <email>yvardi@rambam.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilan Gruenwald, MD</last_name>
      <phone>00972544474341</phone>
      <email>i_gruuenwald@rambam.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Yoram Vardi, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ilan Gruenwald, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Boaz Appel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ezra Gerber, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Omar Massarwa, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yaron Ofer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2011</study_first_submitted>
  <study_first_submitted_qc>January 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2011</study_first_posted>
  <last_update_submitted>May 17, 2011</last_update_submitted>
  <last_update_submitted_qc>May 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof Yoram Vardi</name_title>
    <organization>Rambam Healthcare Campus</organization>
  </responsible_party>
  <keyword>Erectile dysfunction</keyword>
  <keyword>Low Intensity Shock Wave</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

